Exchange: NASDAQ·Updated 04:10 PM EST

REVB News

News
all
press releases
Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company developing innovative therapies designed to rebalance the bodys inflammatory response, today announced a strategic shift designed to accelerate development of Gemini, its proprietary...
Business Wire
Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company developing innovative therapies designed to rebalance the bodys inflammatory response, today announced a strategic shift designed to accelerate development of Gemini, its proprietary...
Business Wire
More News
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and nine months ended September 30, 2026. Corporate Highlights...
Business Wire
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The...
Business Wire
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global...
Business Wire
Revelation Biosciences said its 1-for-4 reverse stock split will become effective from January 28, 2026.
Stocktwits
Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could support an application for its acute kidney injury treatment.read more...
Benzinga
The firm also reported that Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli.
Stocktwits
The company is nearing completion of enrollment in its Phase 1b Gemini trial for CKD, with topline results expected shortly.
Stocktwits
Investing.com -- British stocks opened lower on Thursday as investors looked ahead to the Bank of England’s rate decision, with markets broadly anticipating no change in interest rates at the meeting.
investing.com
Investing.com -- Frasers Group PLC (LON:FRAS) said on Thursday that it will not make an offer for a U.K.-based cosmetics and skincare retailer Revolution Beauty Group PLC (LON:REVB).
investing.com

Advertisement|Remove ads.